Biomarker Profiling in Abdominal Aortic Aneurysm Patients
Study of Biomarker Profiling to Unravel the Intertwined Pathophysiology of Coronary Artery Disease and Abdominal Aortic Aneurysm
The BIOMArCS-AAA study aims to investigate the associations of (temporal patterns of) blood biomarkers with aneurysm growth in patients with abdominal aortic aneurysm (AAA), with particular attention to biomarkers that have demonstrated prognostic value for adverse disease outcomes in coronary artery disease and biomarkers for the main genetic pathways associated with AAA.
BIOMArCS-AAA is an observational, multicenter study. Patients with an abdominal aortic aneurysm (AAA) will be recruited through the vascular surgery outpatient clinic of Erasmus MC and Maasstad Ziekenhuis, the Netherlands. The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients and an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), both with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months, plus at 1 month in the EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients, and at 1 month only in EVAR patients. Additionally, a cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
Volume of the aneurysm sac
Maximal diameter of the aneurysm
Abdominal Aortic Aneurysm
Study Arms / Comparison Groups
Description: The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients, with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
March 23, 2017
Primary Completion Date
Inclusion Criteria: - Age of 18 years or older - Capable of understanding and signing informed consent AND one of the following 1. Diagnosis of AAA, with a diameter ≥40mm, based on any imaging technique and treated by watchful waiting strategy (Prospective longitudinal study, Arm 1 watchful waiting group) 2. Planned to undergo EVAR for AAA (Prospective longitudinal study, Arm 2 EVAR group) 3. Underwent EVAR for AAA in past years (Cross-sectional study) Exclusion Criteria: - Patients with isolated iliac artery aneurysm, traumatic aneurysm, anastomotic aneurysm and infectious aneurysm - Patients with a clinical diagnosed thoracic aneurysm (i.e. located in the chest, above the diaphragm) - Coexistent condition with life expectancy ≤ 1 year - Dialysis dependent, (end stage) renal disease patients - Women of childbearing age - Linguistic barrier - Unlikely to appear at all scheduled follow-up visits
18 Years - N/A
Isabella Kardys, MD, PhD, +31650032051, [email protected]
Erasmus Medical Center
Isabella Kardys, MD, PhD, Study Chair, Erasmus Medical Center